Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer's $11 Mil. Oncogene Purchase Adds Oncology Diagnostics Stable

This article was originally published in The Gray Sheet

Executive Summary

Bayer's acquisition of OSI Pharmaceuticals' diagnostic business builds on the firms' collaborative efforts to run OSI's HER-2/neu breast cancer assay on Bayer's Technicon Immuno I automated immunoassay.

You may also be interested in...

Oncogene licenses cancer detection technology to Bayer for inclusion on Technicon Immuno 1 analyzer.

ONCOGENE SCIENCE CANCER DIAGNOSTIC R&D DEAL WITH BAYER provides a fully automated serum-based analyzer, Bayer's Technicon Immuno 1, for Oncogene's in vitro cancer detection technology. The deal replaces a development pact with Becton Dickinson that had been in place since 1984. In September, Oncogene chose not to renew the deal with BD because the firm does not offer an automated immunoassay system.

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts